Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 468.03 Billion KRW | 9.01% |
| 2022 | 429.34 Billion KRW | 24.33% |
| 2021 | 345.32 Billion KRW | 56.84% |
| 2020 | 220.17 Billion KRW | 42.85% |
| 2019 | 154.13 Billion KRW | 122.08% |
| 2018 | 69.4 Billion KRW | 46.28% |
| 2017 | 47.44 Billion KRW | -23.0% |
| 2016 | 61.61 Billion KRW | 25.11% |
| 2015 | 49.25 Billion KRW | 4.17% |
| 2014 | 47.27 Billion KRW | 30.38% |
| 2013 | 36.26 Billion KRW | -80.51% |
| 2012 | 186.08 Billion KRW | -1.4% |
| 2011 | 188.72 Billion KRW | 11.31% |
| 2010 | 169.54 Billion KRW | 18.84% |
| 2009 | 142.66 Billion KRW | -10.51% |
| 2008 | 159.41 Billion KRW | 4.54% |
| 2007 | 152.49 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 471.84 Billion KRW | 2.89% |
| 2024 Q1 | 458.6 Billion KRW | -2.01% |
| 2023 FY | 468.03 Billion KRW | 9.01% |
| 2023 Q2 | 454.67 Billion KRW | 1.44% |
| 2023 Q1 | 448.21 Billion KRW | 4.4% |
| 2023 Q4 | 468.03 Billion KRW | -2.92% |
| 2023 Q3 | 482.12 Billion KRW | 6.04% |
| 2022 Q1 | 339.14 Billion KRW | -1.79% |
| 2022 Q2 | 392.44 Billion KRW | 15.72% |
| 2022 Q4 | 429.34 Billion KRW | 5.74% |
| 2022 Q3 | 406.01 Billion KRW | 3.46% |
| 2022 FY | 429.34 Billion KRW | 24.33% |
| 2021 Q4 | 345.32 Billion KRW | 6.36% |
| 2021 Q3 | 324.68 Billion KRW | 23.97% |
| 2021 Q2 | 261.89 Billion KRW | 12.98% |
| 2021 Q1 | 231.8 Billion KRW | 5.28% |
| 2021 FY | 345.32 Billion KRW | 56.84% |
| 2020 Q1 | 177.45 Billion KRW | 15.13% |
| 2020 Q2 | 212.13 Billion KRW | 19.54% |
| 2020 FY | 220.17 Billion KRW | 42.85% |
| 2020 Q3 | 225.5 Billion KRW | 6.3% |
| 2020 Q4 | 220.17 Billion KRW | -2.36% |
| 2019 Q2 | 103.35 Billion KRW | 4.29% |
| 2019 FY | 154.13 Billion KRW | 122.08% |
| 2019 Q4 | 154.13 Billion KRW | 11.38% |
| 2019 Q1 | 99.1 Billion KRW | 42.79% |
| 2019 Q3 | 138.37 Billion KRW | 33.89% |
| 2018 FY | 69.4 Billion KRW | 46.28% |
| 2018 Q1 | 41.25 Billion KRW | -13.05% |
| 2018 Q2 | 54.42 Billion KRW | 31.92% |
| 2018 Q3 | 61.46 Billion KRW | 12.93% |
| 2018 Q4 | 69.4 Billion KRW | 12.92% |
| 2017 FY | 47.44 Billion KRW | -23.0% |
| 2017 Q4 | 47.44 Billion KRW | -17.63% |
| 2017 Q3 | 57.6 Billion KRW | -21.26% |
| 2017 Q2 | 73.15 Billion KRW | -0.7% |
| 2017 Q1 | 73.66 Billion KRW | 19.56% |
| 2016 FY | 61.61 Billion KRW | 25.11% |
| 2016 Q4 | 61.61 Billion KRW | 2.43% |
| 2016 Q2 | 50.87 Billion KRW | 15.25% |
| 2016 Q1 | 44.14 Billion KRW | -10.37% |
| 2016 Q3 | 60.15 Billion KRW | 18.24% |
| 2015 FY | 49.25 Billion KRW | 4.17% |
| 2015 Q4 | 49.25 Billion KRW | 40.3% |
| 2015 Q3 | 35.1 Billion KRW | -43.81% |
| 2015 Q2 | 62.47 Billion KRW | 40.04% |
| 2015 Q1 | 44.61 Billion KRW | -5.64% |
| 2014 Q4 | 47.27 Billion KRW | 15.92% |
| 2014 FY | 47.27 Billion KRW | 30.38% |
| 2014 Q3 | 40.78 Billion KRW | 8.09% |
| 2014 Q2 | 37.73 Billion KRW | 22.21% |
| 2014 Q1 | 30.87 Billion KRW | -14.86% |
| 2013 Q2 | 173.02 Billion KRW | -2.67% |
| 2013 Q3 | 165.42 Billion KRW | -4.39% |
| 2013 Q4 | 36.26 Billion KRW | -78.08% |
| 2013 FY | 36.26 Billion KRW | -80.51% |
| 2013 Q1 | 177.78 Billion KRW | -4.46% |
| 2012 FY | 186.08 Billion KRW | -1.4% |
| 2012 Q4 | 186.08 Billion KRW | 0.0% |
| 2012 Q1 | 126.23 Billion KRW | 0.0% |
| 2011 Q1 | 126.4 Billion KRW | 0.0% |
| 2011 Q3 | 126.23 Billion KRW | -0.13% |
| 2011 FY | 188.72 Billion KRW | 11.31% |
| 2011 Q2 | 126.4 Billion KRW | 0.0% |
| 2010 Q2 | 126.4 Billion KRW | -3.67% |
| 2010 Q1 | 131.2 Billion KRW | 0.0% |
| 2010 FY | 169.54 Billion KRW | 18.84% |
| 2010 Q3 | 128.39 Billion KRW | 1.58% |
| 2009 Q1 | 102.55 Billion KRW | 0.0% |
| 2009 FY | 142.66 Billion KRW | -10.51% |
| 2009 Q3 | 101.29 Billion KRW | 1.59% |
| 2009 Q2 | 99.71 Billion KRW | -2.78% |
| 2008 Q1 | 99.81 Billion KRW | 0.0% |
| 2008 Q2 | 97.73 Billion KRW | -2.08% |
| 2008 Q3 | 97.68 Billion KRW | -0.06% |
| 2008 FY | 159.41 Billion KRW | 4.54% |
| 2007 Q3 | 101.05 Billion KRW | -1.64% |
| 2007 FY | 152.49 Billion KRW | 0.0% |
| 2007 Q1 | 105.11 Billion KRW | 0.0% |
| 2007 Q2 | 102.74 Billion KRW | -2.25% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1087.688% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 32.353% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | -22.503% |
| HANDOK Inc. | 300.01 Billion KRW | -56.006% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -1426.426% |
| Yuhan Corporation | 230.07 Billion KRW | -103.43% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | -15.079% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -78497.001% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 18.3% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -36166.809% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -449.595% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -981.589% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -417.266% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -1663.965% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1087.688% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -196448.862% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | -107.965% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -158.586% |
| JW Holdings Corporation | 554.58 Billion KRW | 15.607% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -114.851% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | -112.971% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -174.861% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -914.126% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -1093.814% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -166.111% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -450.851% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1087.688% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | -98.621% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 0.352% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -174.861% |
| Yuhan Corporation | 230.07 Billion KRW | -103.43% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -170.492% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -599.79% |
| Suheung Co., Ltd. | 467.85 Billion KRW | -0.038% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -174.861% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -294.505% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -1060.251% |
| CKD Bio Corp. | 146.92 Billion KRW | -218.549% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -220.462% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -869.911% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -73953.013% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -914.126% |
| Boryung Corporation | 204.21 Billion KRW | -129.186% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -489.561% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -449.595% |
| JW Lifescience Corporation | 46.31 Billion KRW | -910.592% |